ARBUTUS BIOPHARMA CORP (ABUS)

Company Profile

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. The company is headquartered in Warminster, Pennsylvania and currently employs 96 full-time employees. The company went IPO on 2010-11-13. The firm is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, an oral capsid inhibitor, an oral programmed death-ligand-1 (PD-L1) inhibitor, and an oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The firm is also having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses, including SARS-CoV-2.

Company Info

ARBUTUS BIOPHARMA CORP

701 Veterans Circle

Warminster PENNSYLVANIA 18974

P: 16044193200

CEO: William H. Collier

Employees: 96

Website: https://www.arbutusbio.com/